trial

A Long-Term, Open-Label, Study on Schizophrenia

NCTId NCT01129674
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 1,210 (estimated)
Sponsored by Eli Lilly and Company
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
1,210 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2010-06
Primary completion
2012-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadOlanzapineAripiprazoleRisperidoneQuetiapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

81 total
Little Rock, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesNational City, United StatesOakland, United StatesOceanside, United StatesParamount, United StatesPasadena, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United States

Linked catalysts

1
A Long-Term, Open-Label, Study on Schizophrenia — primary completion2012-10

Facts & assertions

4 sourced
Enrollment
1,210
Phase
PHASE2,PHASE3
Primary Completion Date
2012-10
Status
TERMINATED
relationships
The graph out of here
drug
Pomaglumetad
drug
Olanzapine
drug
Aripiprazole
drug
Risperidone
drug
Quetiapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person